Connect Biopharma regains Nasdaq minimum bid price compliance; delisting risk removed

Connect Biopharma Holdings Ltd

Received Nasdaq letter on July 17, 2025 confirming compliance with Minimum Bid Price Requirement.
Regained compliance after ADSs closed at or above $1.00 for 10 consecutive business days through July 15, 2025.
Non-compliance was first notified on March 24, 2025; cure period ran to September 22, 2025.
Matter is now closed; no further action required to maintain listing.
Removal of delisting risk supports continued trading on Nasdaq Global Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.